Abliva AB (Nasdaq Stockholm: ABLI), a clinical-stage biopharmaceutical company developing medicines for the treatment of rare and severe primary mitochondrial diseases, today announced that the Board ...
Abliva AB (Nasdaq Stockholm: ABLI) today announced that the license agreement with Fortify Therapeutics, a wholly-owned subsidiary of BridgeBio, regarding a development of a local treatment for Leber’ ...
Abliva can look back on an eventful year, which was marked by the strategy shift towards treatments for mitochondrial diseases made last year. Several important milestones have been passed - including ...
Abliva AB (Nasdaq Stockholm: ABLI), a clinical-stage biopharmaceutical company developing medicines for the treatment of rare and severe primary mitochondrial diseases, today announced it has received ...
Abliva AB (Nasdaq Stockholm: ABLI), a clinical-stage biopharmaceutical company developing medicines for the treatment of rare and severe primary mitochondrial diseases, today announces dosing in the f ...
Abliva AB (Nasdaq Stockholm: ABLI) today announces that Magnus Persson is leaving the company's Board of Directors at his own request, to focus on his role as founding Partner at Eir Ventures, a recen ...
Abliva AB (Nasdaq Stockholm: ABLI) today announced that the first primary mitochondrial disease patient in the company’s ongoing KL1333 Phase Ia/b study has been dosed. In this third part of the study ...
Abliva AB (Nasdaq Stockholm: ABLI) welcomes, on the occasion of The World Mitochondrial Disease Week, to its virtual Mitochondria Day 2020, today on 16 September at 2 p.m. – 4 p.m. CEST. The purpose o ...
Abliva AB (Nasdaq Stockholm: ABLI) today announced that the company’s Board of Directors has decided to accelerate the KL1333 clinical program, with the intention to start a pivotal Phase II/III clini ...
Abliva AB (Nasdaq Stockholm: ABLI) welcomes, on the occasion of The World Mitochondrial Disease Week, to its virtual Mitochondria Day 2020, on 16 September at 2 p.m. – 4 p.m. CEST. The purpose of the ...
Cookies
We serve cookies. If you think that's ok, just click "Accept all". You can also choose what kind of cookies you want by clicking "Settings".
Read our cookie policy